Upstream Bio, Inc. UPB shares were trading higher during Wednesday’s premarket session following positive results from the ...

Upstream Bio, Inc. downgraded despite strong Verekitug phase 2 asthma results; assess anti-TSLP competition, dosing edge & catalysts. Click for this UPB update.

Investors pull away from Upstream as a twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing asthma exacerbations.

A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week ...

Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...

– Data support the potential of verekitug’s unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respiratory diseases – “We continue to ...

Upstream Bio is presenting at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, which highlights the company's commitment to disseminating important research and gaining ...

Upstream Bio has sailed to a phase 2 win in sinusitis and plans to push its candidate forward against a competitive current. Investigators randomized 81 adults with chronic rhinosinusitis with nasal ...

Welcome back to The Mining Pod! Today, the gang covers news that Blockspace broke regarding a surprising mixed decision in Crusoe and Upstream Data’s patent dispute. Plus, Lancium gets in on the ...